JDB175

CAS: 2635328-79-7 F: C26H21F3N4O2 W: 478.47

JDB175 is a highly selective BTK inhibitor with oral activity and excellent blood-brain barrier penetration. JDB175 show

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	JDB175 is a highly selective BTK inhibitor with oral activity and excellent blood-brain barrier penetration. JDB175 shows good activity in the mouse model of central nervous system lymphoma without obvious signs of toxicity, effectively inhibits the proliferation of BTK signaling pathway of human lymphoma cells, induces cell cycle arrest, and promotes cell apoptosis [1].
Invitro	DB175 (15-40 μM, 48 h) 在 Namalwa， Raji 细胞中能有效抑制 BTK 的磷酸化，下调 cyclin D1 和CDK2 的表达，上调 P21 的表达[1]。JDB175 (0-60 μM, 48 h, 72 h) 在Namalwa, SU-DHL-4, Raji, Ramos, TMD-8 细胞中对细胞活力有时间和剂量依赖性的抑制作用[1]。JDB175 (15 μM, 48 h) 在 Namalwa, SU-DHL-4, Raji, Ramos 细胞中显著增加了 G0/G1 期分布[1]。JDB175 (20-40 μM, 72 h) 在 Namalwa, SU-DHL-4, Raji, Ramos 细胞中显示出较强的诱导凋亡作用[1]。 0 --> JDB175 相关抗体: Cell Viability Assay[1] Cell Line:
In Vivo	JDB175 (10 mg/kg, 口服, 0.5 h) 在大鼠中具有穿透血脑屏障的强大潜力，在抑制中枢神经系统淋巴瘤方面表现出良好的能力[1]。JDB175 (150 mg/kg, 口服, 3 天) 在裸鼠中枢神经系统淋巴瘤肿瘤模型中对肿瘤表现出有效的抑制作用和良好的安全性[1]。 Animal Model:
Name	JDB175
CAS	2635328-79-7
Formula	C26H21F3N4O2
Molar Mass	478.47
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Xia Y, et al. A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma. MedComm (2020). 2023 Nov 4;4(6):e424.

Protein O-Fucosyltransferase 1

Nicotinoyl azide